Printer Friendly

CYTOGEN REPORTS ON BONE PAIN RELIEF AGENT

 PRINCETON, N.J., June 8 /PRNewswire/ -- At the 40th Annual Meeting of the Society of Nuclear Medicine in Toronto, Canada, CYTOGEN Corporation (NASDAQ: CYTO) reported on the clinical experience relating to the study of Samarium-153 EDTMP, or CYT-424, for the treatment of bone pain associated with bone metastases of cancer.
 CYTOGEN recently acquired U.S. marketing rights to this product, which is currently in Phase III trials in both the U.S. and Europe.
 During a physician tutorial entitled, "Painful Bone Metastases: A Tutorial on Palliation", Dr. Aldo Serafini of the University of Miami School of Medicine stated that CYT-424 has been shown to effectively alleviate or abolish pain associated with bone metastases from a variety of malignancies.
 Serafini stated that CYT-424 is easily prepared, very stable, and shows high skeletal uptake and rapid blood clearance. In studies performed to date, pain palliation has been observed in 70-80 percent of patients who received the radiotherapeutic product, with an onset of pain relief typically seen in 4-7 days.
 CYTOGEN is a biopharmaceutical company engaged in the development of products for the targeted delivery of diagnostic and therapeutic substances directly to sites of disease. CYTOGEN uses its patented and proprietary "linker" technology primarily to develop specific cancer diagnostic imaging and cancer therapeutic products.
 /delval/
 -0- 6/8/93
 /CONTACT: Mary Beals, director of Corporate Communications of CYTOGEN, 609-987-8221/
 (CYTO)


CO: CYTOGEN Corporation; Society of Nuclear Medicine ST: New Jersey IN: MTC SU:

CC -- PH023 -- 6547 06/08/93 12:02 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 8, 1993
Words:249
Previous Article:STANDARD & POOR'S STOCK PRICE INDEX -- NOON, TUESDAY, JUNE 8 /PRN/
Next Article:BRISTOL-MYERS SQUIBB COMPANY CREATESINNOVATIVE SALES CONSULTANT PROGRAM
Topics:


Related Articles
CYTOGEN Receives FDA Clearance For Quadramet
New Treatment for Cancer Bone Pain Receives FDA Clearance; Quadramet May Offer New Hope for Pain Relief for Cancer Patients
New Treatment From DuPont Merck Radiopharmaceuticals Offers Renewed Hope For Relief of Pain From Cancer That Has Spread To The Bone
European Study of CYTOGEN's Quadramet(R) Finds Significant Dose Response in The Relief of Bone Pain Caused by Metastatic Breast Cancer and Prostate...
CYTOGEN Receives Canadian Approval for Quadramet(R)
CYTOGEN and Berlex Laboratories Reach Exclusive Marketing Agreement For Quadramet(R).
Cytogen granted summary judgment of non-infringement of prostate cancer patent.
Cytogen Reacquires Marketing Rights to QUADRAMET(R) Pain Therapy Product.
Cytogen Announces Agreement to Reacquire Marketing Rights to QUADRAMET(R) Pain Therapy Product.
Abstract Evaluating QUADRAMET(R) for Multiple Myeloma to be Presented at 2006 American Society of Hematology (ASH) Annual Meeting.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters